Risen (Suzhou) Pharma Tech Co., Ltd.
4 clinical trials · Sponsor
◉ Watch Risen (Suzhou) Pharma Tech Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| To Evaluate the Safety and Efficacy of RP902 Tablets (NCT07579884) | Risen (Suzhou) Pharma Tech Co., Ltd. | 2026-07-01 |
| A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer. (NCT07207070) | Risen (Suzhou) Pharma Tech Co., Ltd. | 2025-11-12 |
| A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors (NCT06208410) | Risen (Suzhou) Pharma Tech Co., Ltd. | 2024-01-11 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903 (NCT06846099) | Risen (Suzhou) Pharma Tech Co., Ltd. | 2022-12-07 |
Track Risen (Suzhou) Pharma Tech Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.